Chalcogen Bonded Directly To Ring Carbon Of The Piperidine Ring Patents (Class 546/242)
-
Publication number: 20130040990Abstract: A convenient and scalable synthesis of DGJNAc ID from D-glucuronolactone in an overall yield of 20% is provided. DGJNAc is the first highly potent and specific competitive inhibitor of GalNAcases. DGJNAc ID is also a competitive inhibitor of -hexosaminidases. Synthesis and activity of L-DGJNAc IL is also shown. The use of DGJNAc as a potent and specific inhibitor of GalNAcases will allow useful investigation and treatment of a number of diseases, including Schindler Disease.Type: ApplicationFiled: January 28, 2011Publication date: February 14, 2013Inventors: George William John Fleet, Terry Douglas Butters
-
Publication number: 20130023611Abstract: Hindered amines represented by the general formula (I): (wherein R is an alkyl or hydroxyalkyl group having 1 to 30 carbon atoms or alkenyl having 2 to 30 carbon atoms; n is an integer of 1 to 4; when n is 1, R1 is alkyl having 1 to 22 carbon atoms, alkenyl having 2 to 22 carbon atoms, or a group represented by the general formula (III): (R is as defined above), while when n is 2 to 4, R1 is an n-valent organic group having 2 to 20 carbon atoms). When added to synthetic resins or coating materials, the amines can impart long-period stabilizing effect to the resins or the materials and exhibit excellent resistance to extraction with acid rain or chemicals.Type: ApplicationFiled: September 13, 2012Publication date: January 24, 2013Applicant: ADEKA CORPORATIONInventors: Yoshinori NEGISHI, Takashi AYABE, Etsuo TOBITA
-
Publication number: 20130011344Abstract: It comprises the use of D-fagomine or derivatives thereof in the prevention and/or coadjuvant treatment of bacterial infections, as well as to pharmaceutical, veterinary, or food and feed, pet food compositions containing them.Type: ApplicationFiled: March 24, 2011Publication date: January 10, 2013Applicant: BIOGLANEInventors: Sergio Pumarola Segura, Josep Lluis Torres Simón
-
Publication number: 20130012384Abstract: The present invention relates to novel compounds of the formula (I), in which W, X, Y, Z, G, A and t have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the spiroheterocyclic tetronic acid derivates and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or acaricides and/or for preventing unwanted plant growth.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Bayer CropScience AGInventors: Thomas BRETSCHNEIDER, Reiner Fischer, Stefan Lehr, Olga Malsam, Arnd Voerste
-
Patent number: 8349923Abstract: The present invention relates to a novel method of flame retarding a polymeric substrate by adding a small but efficient amount of a synergistic mixture of at least one sterically hindered N-alkoxyamine (NOR), at least a metal salt of hypophosphorous (phosphinic) acid and at least one organo-halogen flame retardant. A further aspect of the invention is the flame retardant composition itself and together with a polymer. The present invention also relates to polymeric articles (e.g. moldings, films, fibers, etc.) that are stabilized against light, heat and oxygen and made flame retardant by incorporation of at least one sterically hindered N-alkoxy amine, at least a metal salt of hypophosphorous acid (phosphinic acid) and at least one organo-halogen flame retardant.Type: GrantFiled: December 12, 2008Date of Patent: January 8, 2013Assignee: BASF SEInventor: Michael Roth
-
Publication number: 20120329783Abstract: The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an ?5, ?6, or ?3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an ?5 subunit can be carried out in vivo or in vitro.Type: ApplicationFiled: June 18, 2012Publication date: December 27, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: ROGER L. PAPKE, Nicole A. Horenstein, Michael M. Francis, Kyung Il Choi
-
Publication number: 20120323013Abstract: Production processes for preparing pharmaceutical compositions containing new molecules capable of inhibiting acetylcholinesterase, thus being useful in the treatment of pathologies associated to cholinergic transmission, such as memory related disorders, neurodegenerative disorders such as Alzheimer's Disease, Miastenia Gravis or in the treatment of intoxications induced by chemical agents of central action.Type: ApplicationFiled: June 13, 2012Publication date: December 20, 2012Applicants: Universidade Estadual Paulists UNESP, Universidade Federal do Rio de Janeiro UFRJInventors: Claudio Viegas, JR., Vanderlan da Silva Bolzani, Eliezer Jesus de Lacerda Barreiro, Newton G. Castro, Maria Claudia Marx Young, Monica Santos Rocha
-
Publication number: 20120316173Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.Type: ApplicationFiled: January 11, 2011Publication date: December 13, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Alessandra Bartolozzi, Angela Berry, Doris Riether, Monika Ermann, James Edward Jenkins, Innocent Mushi
-
Patent number: 8318752Abstract: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.Type: GrantFiled: September 15, 2004Date of Patent: November 27, 2012Assignee: Astrazeneca ABInventor: Bernard Barlaam
-
Publication number: 20120282548Abstract: Provided is a pattern forming method comprising (i) a step of forming a film from an actinic ray-sensitive or radiation-sensitive resin composition, (ii) a step of exposing the film, and (iii) a step of developing the exposed film by using an organic solvent-containing developer, wherein the actinic ray-sensitive or radiation-sensitive resin composition comprises (A) a resin capable of decreasing the solubility for an organic solvent-containing developer by the action of an acid, (B) a compound capable of generating an acid upon irradiation with an actinic ray or radiation, (D) a solvent, and (G) a compound having at least either one of a fluorine atom and a silicon atom and having basicity or being capable of increasing the basicity by the action of an acid.Type: ApplicationFiled: January 7, 2011Publication date: November 8, 2012Applicant: FUJIFILM CORPORATIONInventors: Yuichiro Enomoto, Shinji Tarutani, Sou Kamimura, Kaoru Iwato, Keita Kato, Akinori Shibuya
-
Publication number: 20120268706Abstract: The invention relates to compounds of the formula I, and to a liquid-crystalline medium, preferably having a nematic phase and negative dielectric anisotropy, which comprises one or more compounds of formula I, defined herein, for use in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALO, FFS or IPS effect, and to the use of the compounds of the formula I for the stabilization of a liquid-crystalline medium which comprises one or more compounds of the formula II and one or more compounds of the formulae III-1 to III-4, defined herein.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventors: Mark GOEBEL, Rocco FORTTE, Detlef PAULUTH
-
Patent number: 8288551Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.Type: GrantFiled: July 17, 2009Date of Patent: October 16, 2012Assignee: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Peter Wipf, Marie Celine Frantz
-
Patent number: 8283363Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof.Type: GrantFiled: November 5, 2010Date of Patent: October 9, 2012Assignees: Abbott Laboratories, Abbott GmbH & Co. KGInventors: Helmut Mack, Andreas Kling, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
-
Publication number: 20120238750Abstract: The compound of the present invention is represented by the following general formula (1): [wherein X1 represents a nitrogen atom or a group —CH?; R1 represents a group —Z—R6, wherein Z represents a group —CO—, a group —CH(OH)—, or the like, and R6 represents a 5- to 15-membered monocyclic, dicyclic, or tricyclic, saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms, or sulfur atoms; R2 represents a hydrogen atom, a halogen atom or a lower alkylene group; Y represents a group —O—, a group —CO—, a group —CH(OH)—, a lower alkylene group, or the like; and A represents a group or the like, wherein R3 represents a hydrogen atom, a lower alkoxy group, or the like, p represents 1 or 2, and R4 represents an imidazolyl lower alkyl group or the like.Type: ApplicationFiled: February 29, 2012Publication date: September 20, 2012Inventors: Tae FUKUSHIMA, Shuji Matsumura, Noriaki Takemura, Hideaki Satou, Nobuaki Ito, Takuya Shitsuta, Hironori Tsutsui, Michinori Tanaka, Keizo Kan, Hitoshi Nagao, Kenji Watanabe, Kuninori Tai, Takashi Nakagawa, Hideki Takasu, Makoto Sakamoto, Keisuke Miyajima, Satoshi Yamada, Yutaka Kojima, Koichi Yasumura, Naoto Ohi, Mitsuhiro Okuno, Kazuhisa Sugiyama, Kunihiko Kiyono, Takashi Suzuki, Seiji Akamatsu, Takeshi Kodama, Yasuo Yanagihara, Takumi Sumida
-
Publication number: 20120228151Abstract: An extraction component enabling the concurrent recovery of gold and/or palladium selectively from a hydrochloric acid media containing the base metals and other contaminants. The disclosed extractant disclosed eliminates the conventional multi-step process for such extraction by providing for an extraction method which uses a single solvent extraction reagent. Further enhancing the conventional multi step process, the conventional scrubbing stage is eliminated by a single stripping stage. The resulting solutions can be obtained from leaching many types of material such as copper anode slimes, the treatment of scrap such as electronic circuit boards and plating effluents, PGM, or refractory gold ores.Type: ApplicationFiled: March 7, 2011Publication date: September 13, 2012Inventors: Loghman Moradi, Hiwa Salimi, Mohammad Piltan, Issa Yavari
-
Publication number: 20120220564Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed using a series of compounds containing N-acylated cyclic amines linked to an a?l ring as shown in formula (I).Type: ApplicationFiled: September 17, 2010Publication date: August 30, 2012Applicant: Zalicus Pharmaceuticals Ltd.Inventors: Hassan Pajouhesh, Yongbao Zhu, Yuanxi Zhou, Michael E. Grimwood, Eric Simonson
-
Publication number: 20120202756Abstract: The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.Type: ApplicationFiled: October 5, 2011Publication date: August 9, 2012Inventors: Richard Franklin, Martin Quibell, Robert G. Tyson, Bernard T. Golding
-
Patent number: 8236798Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof.Type: GrantFiled: April 27, 2010Date of Patent: August 7, 2012Assignees: Abbott GmbH & Co. KG, Abbott LaboratoriesInventors: Helmut Mack, Andreas Kling, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
-
Publication number: 20120183904Abstract: A chemically amplified positive resist composition of better performance can be formulated using a polymer having a quencher incorporated therein, specifically a polymer comprising recurring units having a carbamate structure which is decomposed with an acid to generate an amino group and optionally recurring units having an acid labile group capable of generating a carboxyl and/or hydroxyl group under the action of an acid. The polymer is highly effective for suppressing diffusion of acid and diffuses little itself, and the composition forms a pattern of rectangular profile at a high resolution.Type: ApplicationFiled: January 13, 2012Publication date: July 19, 2012Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Masayoshi Sagehashi, Jun Hatakeyama, Takeru Watanabe, Tomohiro Kobayashi
-
Patent number: 8222430Abstract: The present invention provides a 1-heterodiene derivative represented by formula (2) or salt thereof: (in formula (2), W represents hydrogen atom or the like, A represents oxygen atom or the like, R1 represents an optionally substituted C1-6 alkyl group or the like, m represents an integer of 0 to 10, n represents an integer of 1 to 4, X1 represents oxygen atom or the like, p represents an integer of 0 to 5, R3 represents an optionally substituted C1-6 alkyl group or the like, r presents an integer of 0 to 5, the 1-heterodiene derivative exists in E-form, Z-form or a mixture thereof according to the carbon-carbon undefined double stereo bond in formula (2)).Type: GrantFiled: December 17, 2009Date of Patent: July 17, 2012Assignee: Nippon Soda Co., Ltd.Inventors: Koichi Kutose, Jyun Takahashi, Isami Hamamoto, Makio Yano, Jyunko Morohoshi, Jyun Kanazawa
-
Patent number: 8216596Abstract: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products.Type: GrantFiled: May 11, 2006Date of Patent: July 10, 2012Assignee: BASF SEInventors: Joseph A. Lupia, Joseph Suhadolnik, Mervin G. Wood, Wanda H. Martin
-
Patent number: 8217170Abstract: The instant invention discloses a process for the preparation of compounds of the formula (I), wherein the general symbols are as defined in claim 1, which process comprises reacting a sterically hindered amine of the formula (II), wherein the general symbols are as defined in claim 1, with a compound of the formula (III) wherein the general symbols are as defined in claim 1, in the presence of a catalyst. The compounds of the formula (I) are useful as stabilizers for protecting organic materials, in particular synthetic polymers, reprographic materials or coating materials against oxidative, thermal or light-induced degradation.Type: GrantFiled: November 14, 2007Date of Patent: July 10, 2012Assignee: BASF SEInventor: Massimiliano Sala
-
Publication number: 20120172601Abstract: Disclosed is a novel zinc cluster compound represented by general formula (1): Zn4O (OCOR)6 (RCOOH)n, wherein R represents an alkyl group which has 1 to 4 carbon atoms and may be substituted with a halogen atom, and n represents 0.1 to 1, and also disclosed are a method for producing the compound and a reaction using the compound.Type: ApplicationFiled: May 31, 2010Publication date: July 5, 2012Applicant: TAKASAGO INTERNATIONAL CORPORATIONInventors: Yoshimasa Matsushima, Hideki Nara, Takahiro Fujiwara
-
Publication number: 20120165533Abstract: Provided are an optically active diazabicyclooctane derivative defined by formula (F) below, which is useful as a pharmaceutical intermediate for ?-lactamase inhibitor, and a process for preparing the same. In formula (F) above, R1 represents CO2R, CO2M, or CONH2, wherein R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or a 2,5-dioxopyrrolidin-1-yl group, and M represents a hydrogen atom, an inorganic cation, or an organic cation; and R2 represents a benzyl group or an allyl group.Type: ApplicationFiled: June 30, 2011Publication date: June 28, 2012Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Masayuki Okue, Yoshiaki Sakamaki
-
Patent number: 8202513Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.Type: GrantFiled: October 3, 2008Date of Patent: June 19, 2012Assignee: Bionomics LimitedInventors: Bernard Luke Flynn, Jonathan Bayldon Baell, Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Andrew John Harvey, Jorgen Alvar Mould, Dharam Paul
-
Publication number: 20120149908Abstract: In a first aspect, the present invention relates to a method for the preparation of alkynylpiperidine and alkynylpiperidine derivatives. In particular, a method is provided for preparing alkynylpiperidine derivatives starting from epoxide compounds. Further, the alkynylpiperidine derivatives according to the present inventions are substituted trans-3-4-alkynylpiperidine derivatives. In another aspect, triazolylpiperidine compounds and methods for said preparation are provided. In particular, the triazolylpiperidine compounds according to the present invention are obtained by reacting an alkynylpiperidine derivatives with an organic azid, preferably, in the presence of a Cu (I) or Ru catalyst. In a preferred embodiment, 1,4-disubstituted or 1,5-disubstituted 1,2,3-triazolylpiperidine compounds are provided.Type: ApplicationFiled: December 13, 2011Publication date: June 14, 2012Inventors: Leiv K. Sydnes, Bengt Erik Haug, Rianne Harmsen
-
Publication number: 20120071319Abstract: Compounds of the formula (I) useful as pesticides are disclosed, wherein the substituents are as defined in claim 1.Type: ApplicationFiled: May 21, 2010Publication date: March 22, 2012Applicant: SYNGENTA CROP PROTECTION, LLCInventors: Jürgen Harry Schaetzer, Thomas Pitterna, Long Lu, Yaming Wu, Peter Renold, Francesca Perruccio, Jérome Yves Cassayre, Michel Mueglebach
-
Publication number: 20120058144Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures XIV or XVII.Type: ApplicationFiled: November 10, 2009Publication date: March 8, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Narayanannair, Marco A. Ciufolini
-
Publication number: 20120053180Abstract: This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.Type: ApplicationFiled: March 17, 2011Publication date: March 1, 2012Applicant: CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD.Inventors: Sang Uk Kang, Min Jeong Kim, Byung Nam Kang, Wei Tan, Albert Charles Gyorkos, Suk Young Cho
-
Publication number: 20120053350Abstract: A process for the preparation of alkyl esters of N-protected oxo-azacycloalkylcarboxylic acids of Formula III: comprises contacting a ketosulfoxonium ylide of Formula II: with an iridium catalyst to obtain Compound III, wherein PG1 is an amine protective group; k is 0, 1, or 2; and RU, R1, R2, and R3 are defined herein. An embodiment of the process further com rises contacting a compound of Formula I: with a sulfoxonium halide of formula (RU)3S(O)Z, wherein Z is halide, in the presence of a strong base to obtain Compound II. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as ?-lactamase inhibitors.Type: ApplicationFiled: April 26, 2010Publication date: March 1, 2012Inventors: Ian Mangion, Mark A. Huffman, Rebecca T. Ruck, Joseph Lynch, John Y.L. Chung, Benjamin Marcune
-
Publication number: 20120046314Abstract: Pharmaceutical compositions are provided that are useful in treating or preventing neoplastic disease, such as cancer. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cancer. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cancer. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cancer is esophageal cancer, hepatocellular carcinoma, colon cancer, prostate cancer, lung cancer, gastric carcinoma, renal cell carcinoma, bone cancer, breast cancer, cervical cancer, brain cancer, or a cancer associated with the tumor suppressor gene p53.Type: ApplicationFiled: February 2, 2006Publication date: February 23, 2012Applicant: MITOS, INC.Inventors: Louis Habash, Clarence Jones
-
Publication number: 20120038996Abstract: The present invention relates to a radically polymerizable composition comprising a hydroxylamine ester used to manufacture color filters. The invention further relates to novel hydroxylamine esters. The invention further relates to the use of hydroxylamine esters in all liquid crystal display components requiring post-baking.Type: ApplicationFiled: March 17, 2010Publication date: February 16, 2012Applicant: BASF SEInventors: Hisatoshi Kura, Kaori Sameshima, Kazuhiko Kunimoto, Peter Nesvadba, Masaki Ohwa
-
Publication number: 20120029021Abstract: Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the products formed from the adducts after administration.Type: ApplicationFiled: January 17, 2011Publication date: February 2, 2012Applicant: THE TRUSTEES OF CALIFORNIA STATE UNIVERSITYInventors: Yong Ba, Errol V. Mathias
-
Publication number: 20120015911Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.Type: ApplicationFiled: September 20, 2011Publication date: January 19, 2012Applicant: Bellus Health Inc.Inventors: Xianqi Kong, Xinfu Wu, Abderrahim Bouzide, Isabelle Valade, David Migneault, Francine Gervais, Daniel Delorme, Benoit Bachand, Mohamed Atfani, Sophie Levesque, Bita Samim
-
Publication number: 20110294800Abstract: The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood glucose levels in a subject, by administering an effective amount of a compound of formula I.Type: ApplicationFiled: August 7, 2009Publication date: December 1, 2011Applicant: The Trustees Of Columbia University in the City of New YorkInventors: Yuli Xie, Shixian Deng, Donald W. Landry, Paul Harris, Antonella Maffei
-
Publication number: 20110288251Abstract: The invention relates to novel O-dialkylamino-isoureas and polymerizable compositions comprising these O-dialkylamino-isoureas of compounds of the general formula (I). The invention further relates to the use of O-dialkylamino-isoureas as polymerization initiators, especially to prepare coatings or for controlled degradation of polyolefins.Type: ApplicationFiled: December 28, 2009Publication date: November 24, 2011Applicant: BASF SEInventors: Peter Nesvadba, Lucienne Bugnon Folger, Antoine Carroy, Marc Faller
-
Publication number: 20110275797Abstract: An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl group or the like; R2 represents a hydrogen atom or the like; R3 represents an optionally substituted aryl group or the like; X1 represents a carbonyl group; X2 represents a bonding hand; X3 represents a bonding hand; X4 represents a bonding hand or the like; and A represents an optionally substituted phenyl group or the like.Type: ApplicationFiled: January 29, 2010Publication date: November 10, 2011Applicant: Toyama Chemical Co., Ltd.Inventors: Junichi Yokotani, Arihiro Takatori, Yukie Tada, Minori Yanai, Hiroshi Kato, Yoichi Taniguchi, Chiharu Tanabe
-
Publication number: 20110269722Abstract: The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.Type: ApplicationFiled: December 23, 2010Publication date: November 3, 2011Inventor: Apparao Satyam
-
Patent number: 8044070Abstract: Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.Type: GrantFiled: August 13, 2009Date of Patent: October 25, 2011Assignee: MSD K.K.Inventors: Norikazu Ohtake, Akira Naya, Yuji Haga, Makoto Jitsuoka, Takuya Suga, Ryo Yoshimoto, Shigeru Tokita, Akio Kanatani
-
Publication number: 20110251068Abstract: Disclosed is a parasitic plant control agent which can control a parasitic plant effectively. Also disclosed is a parasitic plant control method. A parasitic plant can be controlled by inhibiting the metabolism of gentianose in the parasitic plant to inhibit the germination of the parasitic plant.Type: ApplicationFiled: October 5, 2009Publication date: October 13, 2011Applicant: OSAKA UNIVERSITYInventors: Atsushi Okazawa, Joseph Benesh
-
Publication number: 20110245444Abstract: A method for processing biomass comprising heating an aqueous slurry comprising biomass, water and a phosphate catalyst in a pressure vessel at a temperature of about 150° C. to about 500° C. to produce a mixture comprising a dispersion of an organic phase and an aqueous phase.Type: ApplicationFiled: September 11, 2009Publication date: October 6, 2011Applicant: AQUAFLOW BIONOMIC CORPORATION LIMITEDInventors: Ian James Miller, Rhys Antony Batchelor
-
Publication number: 20110224079Abstract: Novel compounds of the formula (I), wherein the substituents are as defined in claim 1; compositions containing them and their use as insecticides, acaricides, nematicides or molluscicides.Type: ApplicationFiled: November 30, 2009Publication date: September 15, 2011Applicant: SYNGENTA CROP PROTECTION LLCInventors: Michel Muehlebach, Thomas Pitterna, Andre Jeanguenat, Myriem El Qacemi, Roger Graham Hall, Andrew Edmunds, Camilla Corsi, Andre Stoller, Christopher Richard Godfrey, Jurgen Harry Schaetzer, Olivier Loiseleur, Peter Maienfisch, Jerome Yves Cassayre
-
Patent number: 8012993Abstract: The present invention relates to stable S-nitrosothiols derivatives of formula (I) having vasodilating effect and which inhibit the aggregation of the platelets and which therefore are useful for the preparation of medicaments for treatment of NO related diseases. The invention also relates to a process for the synthesis of the compounds of formula (I).Type: GrantFiled: March 1, 2007Date of Patent: September 6, 2011Assignee: Lacer, S.A.Inventors: José Repollés Moliner, Francisco Pubill Coy, Marisabel Mourelle Mancini, Juan Carlos del Castillo Nieto, Lydia Cabeza Llorente, Juan Martínez Bonín, Ana Modolell Saladrigas
-
Publication number: 20110213153Abstract: Production processes for preparing pharmaceutical compositions containing new molecules capable of inhibiting acetylcholinesterase, thus being useful in the treatment of pathologies associated to cholinergic transmission, such as memory related disorders, neurodegenerative disorders such as Alzheimer's Disease, Miastenia Gravis or in the treatment of intoxications induced by chemical agents of central action.Type: ApplicationFiled: May 10, 2011Publication date: September 1, 2011Applicants: Universidade Federal do Rio de Janeiro UFRJ, Universidade Estadual Paulista-UNESPInventors: Cláudio Viegas, JR., Vanderlan da Silva Bolzani, Eliezer Jesus de Lacerda Barreiro, Newton G. Castro, Maria Cláudia Marx Young, Mônica Santos Rocha
-
Publication number: 20110200484Abstract: A disinfecting, nonbleaching N-halamine for use in contact lens soaking solutions. The N-halamine compound is soluble in water and contact lens formulation solutions to the extent necessary to provide disinfection, but not to cause significant bleaching of dye materials incorporated into the contact lenses.Type: ApplicationFiled: February 17, 2011Publication date: August 18, 2011Applicant: Auburn UniversityInventors: Shelby D. Worley, Xuehong Ren, Hasan B. Kocer
-
Publication number: 20110195929Abstract: Described are various compounds and methods for the treatment of flaviviral infections. In particular, alkaloids and imino sugars in arabinose and/or lyxose stereochemical configuration with antiflaviviral activity are described.Type: ApplicationFiled: August 4, 2009Publication date: August 11, 2011Applicant: SUMMIT CORPORATION PLCInventors: Olivier De Moor, Graeme Horne, Penny Jane Middleton, Frank Schroer, Stephen Paul Wren, Maria Ines Passos Eleuterio, Renate Van Well, Colin Richard Dorgan, Francis Xavier Wilson, Robert Nash, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Akane Kawamura, Jonathon Mark Tinsley
-
Publication number: 20110172230Abstract: [Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and/or overactive bladder. [Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and/or overactive bladder.Type: ApplicationFiled: August 22, 2007Publication date: July 14, 2011Inventors: Takahiro Ishii, Takashi Sugane, Akio Kakefuda, Tatsuhisa Takahashi, Tokatoshi Kanayama, Kentaro Sato, Ikumi Kuriwaki, Chika Kitada, Jotaro Suzuki
-
Publication number: 20110172431Abstract: A process is provided for producing a 1-substituted trans-4-(substituted amino)piperidin-3-ol represented by formula (III-1): The process includes a step of reacting a 1-substituted-3,4-epoxypiperidine represented by formula (I): with an amine compound represented by formula (II) in the presence of an inorganic lithium salt. By utilizing the process, trans-4-aminopiperidin-3-ol compounds useful as various chemical products, such as medicine intermediates, can be produced.Type: ApplicationFiled: September 25, 2009Publication date: July 14, 2011Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Toshiaki Aikawa, Osamu Tokuda, Tetsuya Ikemoto
-
Publication number: 20110166357Abstract: An N-substituted-trans-4-azidopiperidin-3-ol represented by formula (II-1) R1 is as defined below, which is useful as a pharmaceutical intermediate and so on, is produced by reacting an N-substituted-3,4-epoxypiperidine represented by formula (I): wherein R1 represents an aralkyl group having 7 to 24 carbon atoms or an alkyl group having 1 to 12 carbon atoms, with sodium azide in the presence of an inorganic lithium salt.Type: ApplicationFiled: September 2, 2009Publication date: July 7, 2011Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Osamu Tokuda, Toshiaki Aikawa, Tetsuya Ikemoto
-
Publication number: 20110129419Abstract: The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states.Type: ApplicationFiled: December 19, 2007Publication date: June 2, 2011Applicants: GE HEALTHCARE LIMITED, HAMMERSMITH IMANET LIMITEDInventors: Anthony Eamon Storey, Julie Davis, Erik Arstad, Benedicte Guilbert, Alessandra Gaeta